Cytokinetics shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $58 price target.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.